{"id":924133,"date":"2026-01-06T09:43:25","date_gmt":"2026-01-06T14:43:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/"},"modified":"2026-01-06T09:43:25","modified_gmt":"2026-01-06T14:43:25","slug":"anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/","title":{"rendered":"Anavex Life Sciences Receives FDA Feedback on Alzheimer\u2019s Disease Program"},"content":{"rendered":"
\n

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) had invited the Company to present the Company\u2019s Alzheimer’s disease clinical trial results, reflecting the Agency\u2019s interest in the progress of Anavex\u2019s clinical development efforts.<\/p>\n

During the Type C meeting, the FDA shared their interest and collaborative approach to Anavex\u2019 development plans. The Company provided information related to the scientific rationale and profile of blarcamesine as an oral administration being convenient to dispense and the absence of significant safety concerns in clinical trials of blarcamesine conducted so far extending to the lack of amyloid-related imaging abnormalities (ARIA).<\/p>\n

The meeting discussed the potential pathways to support an NDA (New Drug Application) for the treatment of Alzheimer\u2019s disease. In order to move forward, existing data from the Phase IIb\/III ANAVEX2-73-AD-004 program requested by the Agency will be submitted. The Company committed to continue the initiated constructive exchange with the Agency in order to facilitate the timely evaluation and advance the Alzheimer\u2019s disease program.<\/p>\n

Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, commented: \u201cWe are encouraged by the FDA\u2019s constructive feedback and interest in our Alzheimer\u2019s disease program. This collaborative dialogue reinforces our commitment to advancing innovative therapies for neurodegenerative diseases and positions us well for the next phase of regulatory interactions.\u201d<\/p>\n

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.<\/p>\n

\n About Alzheimer\u2019s disease<\/strong>\n <\/p>\n

Alzheimer’s disease is the most common cause of dementia, accounting for 60-80% of all dementia cases worldwide. Dementia is a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer\u2019s disease is a progressive disease, where symptoms gradually worsen over time. Each stage of the disease presents different challenges for those living with the disease and their care partners. There is a significant unmet need for new treatment options that can slow down the progression of Alzheimer\u2019s disease and reduce the overall burden on people affected and on society.<\/p>\n

\n About Anavex Life Sciences Corp.<\/strong>\n <\/p>\n

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex’s lead drug candidate, ANAVEX\u00ae<\/sup>2-73 (blarcamesine<\/em>), has successfully completed a Phase 2a and a Phase 2b\/3 clinical trial for Alzheimer’s disease, a Phase 2 proof-of-concept study in Parkinson’s disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2\/3 study in pediatric patients with Rett syndrome. ANAVEX\u00ae<\/sup>2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and\/or reverse the course of Alzheimer’s disease. ANAVEX\u00ae<\/sup>2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX\u00ae<\/sup>2-73 for the treatment of Parkinson’s disease. We believe that ANAVEX\u00ae<\/sup>3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX\u00ae<\/sup>3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com<\/u><\/a>. You can also connect with the Company on Twitter<\/u><\/a>, Facebook<\/u><\/a>, Instagram<\/u><\/a>, and LinkedIn<\/u><\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company\u2019s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.<\/p>\n

\n For Further Information:<\/strong>
\n
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com<\/u><\/a><\/p>\n

\n Investors:<\/strong>
\n
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) had invited the Company to present the Company\u2019s Alzheimer’s disease clinical trial results, reflecting the Agency\u2019s interest in the progress of Anavex\u2019s clinical development efforts. During the Type C meeting, the FDA shared their interest and collaborative approach to Anavex\u2019 development plans. The Company provided information related to the scientific rationale and profile of blarcamesine as an oral administration being convenient to … <\/p>\n

Continue reading “Anavex Life Sciences Receives FDA Feedback on Alzheimer\u2019s Disease Program”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-924133","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAnavex Life Sciences Receives FDA Feedback on Alzheimer\u2019s Disease Program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anavex Life Sciences Receives FDA Feedback on Alzheimer\u2019s Disease Program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) had invited the Company to present the Company\u2019s Alzheimer’s disease clinical trial results, reflecting the Agency\u2019s interest in the progress of Anavex\u2019s clinical development efforts. During the Type C meeting, the FDA shared their interest and collaborative approach to Anavex\u2019 development plans. The Company provided information related to the scientific rationale and profile of blarcamesine as an oral administration being convenient to … Continue reading "Anavex Life Sciences Receives FDA Feedback on Alzheimer\u2019s Disease Program"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-06T14:43:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMDI5OCM3MzQ1ODU4IzIwMTk1Mzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Anavex Life Sciences Receives FDA Feedback on Alzheimer\u2019s Disease Program\",\"datePublished\":\"2026-01-06T14:43:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\\\/\"},\"wordCount\":851,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMDI5OCM3MzQ1ODU4IzIwMTk1Mzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\\\/\",\"name\":\"Anavex Life Sciences Receives FDA Feedback on Alzheimer\u2019s Disease Program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMDI5OCM3MzQ1ODU4IzIwMTk1Mzk=\",\"datePublished\":\"2026-01-06T14:43:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMDI5OCM3MzQ1ODU4IzIwMTk1Mzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMDI5OCM3MzQ1ODU4IzIwMTk1Mzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anavex Life Sciences Receives FDA Feedback on Alzheimer\u2019s Disease Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anavex Life Sciences Receives FDA Feedback on Alzheimer\u2019s Disease Program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/","og_locale":"en_US","og_type":"article","og_title":"Anavex Life Sciences Receives FDA Feedback on Alzheimer\u2019s Disease Program - Market Newsdesk","og_description":"NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) had invited the Company to present the Company\u2019s Alzheimer’s disease clinical trial results, reflecting the Agency\u2019s interest in the progress of Anavex\u2019s clinical development efforts. During the Type C meeting, the FDA shared their interest and collaborative approach to Anavex\u2019 development plans. The Company provided information related to the scientific rationale and profile of blarcamesine as an oral administration being convenient to … Continue reading \"Anavex Life Sciences Receives FDA Feedback on Alzheimer\u2019s Disease Program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-06T14:43:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMDI5OCM3MzQ1ODU4IzIwMTk1Mzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Anavex Life Sciences Receives FDA Feedback on Alzheimer\u2019s Disease Program","datePublished":"2026-01-06T14:43:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/"},"wordCount":851,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMDI5OCM3MzQ1ODU4IzIwMTk1Mzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/","name":"Anavex Life Sciences Receives FDA Feedback on Alzheimer\u2019s Disease Program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMDI5OCM3MzQ1ODU4IzIwMTk1Mzk=","datePublished":"2026-01-06T14:43:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMDI5OCM3MzQ1ODU4IzIwMTk1Mzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMDI5OCM3MzQ1ODU4IzIwMTk1Mzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Anavex Life Sciences Receives FDA Feedback on Alzheimer\u2019s Disease Program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=924133"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924133\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=924133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=924133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=924133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}